Oracle and AstraZeneca agreed to test AI to find trial patients. AstraZeneca says it won't receive their identities.
The first planned programme is in Abu Dhabi with healthcare company M42.
AstraZeneca says it should help clinical teams find people whose high blood pressure is not under control and sign more of them up for trials. Oracle is to supply the patient data, cloud and AI tools.
Oracle calls patient recruitment one of the largest obstacles in clinical trials. Reuters noted that delayed enrolment often stretches trial timelines and raises development costs.
What the two signed on Tuesday is a non-binding term sheet. AstraZeneca's release says no financials are being disclosed. Neither release names a patient count, a timeline, a target for faster trials or the Oracle products involved.
Oracle says the companies still plan to agree how results will be measured, and each project must pass legal, privacy, regulatory and ethics checks before it starts.
Sources
Our file on Oracle
- 23 Oct
Microsoft, Oracle and 3 peers have $2.7 trillion in AI commitments, a study found. None is on balance sheets yet.
- 22 Oct
Oracle announced seven AI agents for HR and payroll, with no price or date. Oracle says employers stay responsible for their decisions.
- 16 Oct
Oracle gave US tech startups a free NetSuite plan. It allows five users.
- 13 Oct
Oracle settled UCLA's ERP dispute with $3.1m in credits. UCLA spent at least $213m.
- 11 Oct
Oracle spent $28.5 billion in one quarter. Its long-term debt passed $160 billion.
Every story here is open to read. The ERP LEADERS brief goes one step further.
The day in enterprise software, in one email: the stories that matter, the failures with their figures, one case taken apart. Read a sample or sign up for the brief.
Welcome back. · Issue 01
